|19th November 2020||W Thorpe Mckenzie||375,000||Open or private sale||$18.30||$6,862,500.00|
|18th September 2020||John Simard||500,000||Other acquisition or disposition||$0.00|
|15th September 2020||Sushma Shivaswamy||20,668||Open or private sale||$20.00||$413,360.00|
|15th September 2020||Sushma Shivaswamy||20,668||Exercise of derivative||$7.50||$155,010.00|
|10th September 2020||Sushma Shivaswamy||19,332||Exercise of derivative||$7.50||$144,990.00|
|10th September 2020||Sushma Shivaswamy||19,332||Open or private sale||$20.01||$386,833.32|
|1st September 2020||Queena Han||27,692||Exercise of derivative||$4.16||$115,198.72|
|1st September 2020||Queena Han||30,000||Exercise of derivative||$4.24||$127,200.00|
|24th August 2020||Queena Han||18,700||Open or private sale||$19.65||$367,535.41|
|24th August 2020||Queena Han||18,700||Exercise of derivative||$7.50||$140,250.00|
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 10/10.
XBiotech, Inc. is a biopharmaceutical company. Its product pipeline include oncology, infectious diseases, dermatology, and inflammatory disorders.